Peripheral blood biomarkers in multiple sclerosis

Antonella D'Ambrosio, Simona Pontecorvo, Tania Colasanti, Silvia Zamboni, Ada Francia, Paola Margutti

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Multiple sclerosis is the most common autoimmune disorder affecting the central nervous system. The heterogeneity of pathophysiological processes in MS contributes to the highly variable course of the disease and unpredictable response to therapies. The major focus of the research on MS is the identification of biomarkers in biological fluids, such as cerebrospinal fluid or blood, to guide patient management reliably. Because of the difficulties in obtaining spinal fluid samples and the necessity for lumbar puncture to make a diagnosis has reduced, the research of blood-based biomarkers may provide increasingly important tools for clinical practice. However, currently there are no clearly established MS blood-based biomarkers. The availability of reliable biomarkers could radically alter the management of MS at critical phases of the disease spectrum, allowing for intervention strategies that may prevent evolution to long-term neurological disability. This article provides an overview of this research field and focuses on recent advances in blood-based biomarker research.

Original languageEnglish
Pages (from-to)1097-1110
Number of pages14
JournalAutoimmunity Reviews
Volume14
Issue number12
DOIs
Publication statusPublished - Dec 1 2015

Fingerprint

Multiple Sclerosis
Biomarkers
Research
Spinal Puncture
Central Nervous System Diseases
Cerebrospinal Fluid
Therapeutics

Keywords

  • Autoimmune disease
  • Biomarkers
  • Multiple sclerosis
  • Therapy

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

D'Ambrosio, A., Pontecorvo, S., Colasanti, T., Zamboni, S., Francia, A., & Margutti, P. (2015). Peripheral blood biomarkers in multiple sclerosis. Autoimmunity Reviews, 14(12), 1097-1110. https://doi.org/10.1016/j.autrev.2015.07.014

Peripheral blood biomarkers in multiple sclerosis. / D'Ambrosio, Antonella; Pontecorvo, Simona; Colasanti, Tania; Zamboni, Silvia; Francia, Ada; Margutti, Paola.

In: Autoimmunity Reviews, Vol. 14, No. 12, 01.12.2015, p. 1097-1110.

Research output: Contribution to journalArticle

D'Ambrosio, A, Pontecorvo, S, Colasanti, T, Zamboni, S, Francia, A & Margutti, P 2015, 'Peripheral blood biomarkers in multiple sclerosis', Autoimmunity Reviews, vol. 14, no. 12, pp. 1097-1110. https://doi.org/10.1016/j.autrev.2015.07.014
D'Ambrosio A, Pontecorvo S, Colasanti T, Zamboni S, Francia A, Margutti P. Peripheral blood biomarkers in multiple sclerosis. Autoimmunity Reviews. 2015 Dec 1;14(12):1097-1110. https://doi.org/10.1016/j.autrev.2015.07.014
D'Ambrosio, Antonella ; Pontecorvo, Simona ; Colasanti, Tania ; Zamboni, Silvia ; Francia, Ada ; Margutti, Paola. / Peripheral blood biomarkers in multiple sclerosis. In: Autoimmunity Reviews. 2015 ; Vol. 14, No. 12. pp. 1097-1110.
@article{77dcd0dfb68c4ff29d4306e1755ec0ef,
title = "Peripheral blood biomarkers in multiple sclerosis",
abstract = "Multiple sclerosis is the most common autoimmune disorder affecting the central nervous system. The heterogeneity of pathophysiological processes in MS contributes to the highly variable course of the disease and unpredictable response to therapies. The major focus of the research on MS is the identification of biomarkers in biological fluids, such as cerebrospinal fluid or blood, to guide patient management reliably. Because of the difficulties in obtaining spinal fluid samples and the necessity for lumbar puncture to make a diagnosis has reduced, the research of blood-based biomarkers may provide increasingly important tools for clinical practice. However, currently there are no clearly established MS blood-based biomarkers. The availability of reliable biomarkers could radically alter the management of MS at critical phases of the disease spectrum, allowing for intervention strategies that may prevent evolution to long-term neurological disability. This article provides an overview of this research field and focuses on recent advances in blood-based biomarker research.",
keywords = "Autoimmune disease, Biomarkers, Multiple sclerosis, Therapy",
author = "Antonella D'Ambrosio and Simona Pontecorvo and Tania Colasanti and Silvia Zamboni and Ada Francia and Paola Margutti",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.autrev.2015.07.014",
language = "English",
volume = "14",
pages = "1097--1110",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "12",

}

TY - JOUR

T1 - Peripheral blood biomarkers in multiple sclerosis

AU - D'Ambrosio, Antonella

AU - Pontecorvo, Simona

AU - Colasanti, Tania

AU - Zamboni, Silvia

AU - Francia, Ada

AU - Margutti, Paola

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Multiple sclerosis is the most common autoimmune disorder affecting the central nervous system. The heterogeneity of pathophysiological processes in MS contributes to the highly variable course of the disease and unpredictable response to therapies. The major focus of the research on MS is the identification of biomarkers in biological fluids, such as cerebrospinal fluid or blood, to guide patient management reliably. Because of the difficulties in obtaining spinal fluid samples and the necessity for lumbar puncture to make a diagnosis has reduced, the research of blood-based biomarkers may provide increasingly important tools for clinical practice. However, currently there are no clearly established MS blood-based biomarkers. The availability of reliable biomarkers could radically alter the management of MS at critical phases of the disease spectrum, allowing for intervention strategies that may prevent evolution to long-term neurological disability. This article provides an overview of this research field and focuses on recent advances in blood-based biomarker research.

AB - Multiple sclerosis is the most common autoimmune disorder affecting the central nervous system. The heterogeneity of pathophysiological processes in MS contributes to the highly variable course of the disease and unpredictable response to therapies. The major focus of the research on MS is the identification of biomarkers in biological fluids, such as cerebrospinal fluid or blood, to guide patient management reliably. Because of the difficulties in obtaining spinal fluid samples and the necessity for lumbar puncture to make a diagnosis has reduced, the research of blood-based biomarkers may provide increasingly important tools for clinical practice. However, currently there are no clearly established MS blood-based biomarkers. The availability of reliable biomarkers could radically alter the management of MS at critical phases of the disease spectrum, allowing for intervention strategies that may prevent evolution to long-term neurological disability. This article provides an overview of this research field and focuses on recent advances in blood-based biomarker research.

KW - Autoimmune disease

KW - Biomarkers

KW - Multiple sclerosis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84945486839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945486839&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2015.07.014

DO - 10.1016/j.autrev.2015.07.014

M3 - Article

C2 - 26226413

AN - SCOPUS:84945486839

VL - 14

SP - 1097

EP - 1110

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 12

ER -